No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CDMO Avid Bioservices
- 9.450
- -0.050-0.53%
Close Jul 19 16:00 ET
600.84MMarket Cap-4237P/E (TTM)
9.650High9.220Low1.05MVolume9.510Open9.500Pre Close9.90MTurnover1.91%Turnover RatioLossP/E (Static)63.58MShares13.22052wk High9.86P/B522.44MFloat Cap4.07152wk Low--Dividend TTM55.28MShs Float116.375Historical High--Div YieldTTM4.53%Amplitude1.540Historical Low9.399Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Craig-Hallum Maintains Avid Bioservices(CDMO.US) With Buy Rating
Craig-Hallum analyst Matt Hewitt maintains $Avid Bioservices(CDMO.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 42.7% and a total average return of -4.4% over
Craig-Hallum Reaffirms Their Buy Rating on Avid Bioservices (CDMO)
Avid Bioservices (NASDAQ:CDMO) Is Making Moderate Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart
KeyBanc Maintains Avid Bioservices(CDMO.US) With Buy Rating, Maintains Target Price $14
KeyBanc analyst Paul Knight maintains $Avid Bioservices(CDMO.US)$ with a buy rating, and maintains the target price at $14.According to TipRanks data, the analyst has a success rate of 42.1% and a tot
Why Avid Bioservices Stock Is Moving Higher Wednesday
Avid Bioservices, Inc. (NASDAQ:CDMO) shares are trading higher on Wednesday following the company reporting better-than-expected 2024 fiscal-year fourth quarter sales.The Details: Avid reported fourth
Avid Bioservices Shares Rise on Upbeat FY25 Outlook
By Michael Susin Avid Bioservices shares rose on Wednesday after the group said it expects revenue to sharply increase in fiscal 2025 and to generate positive cashflow and despite posting a widened f
Comments
Investors' belief in Societal CDMO's lackluster revenue performance not improving may be causing its low P/S ratio. The company's inferior revenue outlook compared to the industry average contributes to this. A significant change in fortune is needed to justify a higher P/S.
1
The company's high debt and lack of profitability strain its balance sheet. Negative free cash flow adds risk, but its US$417.4m market cap could potentially allow capital raising to strengthen the balance sheet.
Investors' belief in Avid Bioservices' stagnant revenue performance and future growth lagging behind the industry has led to its low P/S. The underwhelming revenue outlook and shareholders' pessimism impact the P/S negatively.
Despite good revenue growth, the market expected more, as seen in the share price drop. This could hint at delayed revenue growth. The recent sell-off might be an investment chance considering the signs of a continued growth trend.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg